Siplizumab combination therapy with belatacept or abatacept broadly inhibits human T cell alloreactivity in vitro
American Journal of Transplantation · 2023
DOI: 10.1016/j.ajt.2023.05.032 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Transplantation, 2023. Verfasst von Filip Cvetkovski und 4 weiteren Autor:innen. Beteiligte Einrichtung: Research and Development, ITB-MED AB, Stockholm, Sweden; Endocrine and Sarcoma Surgery Unit, Department of Molecular Medicine and Surgery, Karolinska…. Hauptthemen laut MEDLINE: CD28 Antigens, Kidney Transplantation. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Combined antigen-specific T cell receptor stimulation and costimulation are needed for complete T cell activation. Belatacept and abatacept are nondepleting fusion proteins blocking CD28/B7 costimulation, whereas siplizumab is a depleting antiCD2 immunoglobulin G1 monoclonal antibody targeting CD2/CD58 costimulation. Herein, the effect of siplizumab combination therapy with abatacept or belatacept on T cell alloreactivity in mixed lymphocyte reactions was investigated. In contrast to monotherapy, the combination of siplizumab with belatacept or abatacept induced near-complete suppression of T cell proliferation and increased the potency of siplizumab-mediated T cell inhibition. Furthermore, dual targeting of CD2 and CD28 costimulation enhanced the selective depletion of memory T cells compared with monotherapy. Although siplizumab monotherapy leads to significant regulatory T cell enrichment, high doses of cytotoxic T-lymphocyte-associated antigen 4 and a human IgG1 Fc fragment in the combination therapy reduced this effect. These results support the clinical evaluation of dual costimulation blockade, combining siplizumab with abatacept or belatacept, for the prophylaxis of organ transplant rejection and improvement of long-term outcomes following transplantation. Ongoing investigative research will elucidate when other forms of siplizumab-based dual costimulatory blockade may be able to induce similarly strong inhibition of T cell activation although still allowing for enrichment of regulatory T cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Research and Development, ITB-MED AB, Stockholm, Sweden; Endocrine and Sarcoma Surgery Unit, Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden.
- Research and Development, ITB-MED AB, Stockholm, Sweden.
- Research and Development, ITB-MED AB, Stockholm, Sweden; Department of Immunology, Genetics and Pathology, Section of Clinical Immunology, Uppsala University, Sweden.
- Research and Development, ITB-MED AB, Stockholm, Sweden; Endocrine and Sarcoma Surgery Unit, Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden; Division of Transplantation Surgery, De…
- Research and Development, ITB-MED AB, Stockholm, Sweden; Department of Immunology, Genetics and Pathology, Section of Clinical Immunology, Uppsala University, Sweden. Electronic address: david.berglund@itb-med.com.
Zitieren
APA
Cvetkovski, F., Razavi, R., Sellberg, F., Berglund, E., & Berglund, D. (2023). Siplizumab combination therapy with belatacept or abatacept broadly inhibits human T cell alloreactivity in vitro. American Journal of Transplantation. https://doi.org/10.1016/j.ajt.2023.05.032
Vancouver
Cvetkovski F, Razavi R, Sellberg F, Berglund E, Berglund D. Siplizumab combination therapy with belatacept or abatacept broadly inhibits human T cell alloreactivity in vitro. American Journal of Transplantation. 2023. doi:10.1016/j.ajt.2023.05.032
BibTeX
@article{Cvetkovski2023,
author = {Cvetkovski, Filip and Razavi, Ronia and Sellberg, Felix and Berglund, Erik and Berglund, David},
title = {Siplizumab combination therapy with belatacept or abatacept broadly inhibits human T cell alloreactivity in vitro},
journal = {American Journal of Transplantation},
year = {2023},
doi = {10.1016/j.ajt.2023.05.032}
}
EUVIMED